Juventas Therapeutics Inc
Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas did not meet the end point criteria in its Phase 2b study in patients with advanced peripheral artery disease.
On November 2018 Astellas Pharma Inc Executed License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas. The agreement grants to Astellas a license to conduct research and to develop JVS-100 through Phase 2a clinical studies with an option to acquire JVS-100 from Juventas for further development and commercialization. Astellas currently plans to focus development efforts on the treatment of fecal incontinence (FI).